| DOI: 10.29090/psa.2023.03.22.331 | Pharm Sci Asia 2023; 50(3), 204-210 |
ABO blood group and effectiveness of tocilizumab in clinical response to COVID-19: A single center, retrospective studyIzza Aulia Rizqika Nasution1, Retnosari Andrajati1,2*, Nadia Farhanah Syafhan1,2, Rania Imaniar2
1 Graduate Program, Division of Clinical Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia
2 Universitas Indonesia Hospital, Jl. Prof. DR. Bahder Djohan, Pondok Cina, Beji, Depok, West Java, Indonesia
As an anticytokine therapy, tocilizumab has been recommended for the management therapy in patients with severe and serious COVID-19 cases. The association between the severity of COVID-19 and blood groups has been the subject of prior research. Therefore, it is important to analyze the relationship between blood types and the effectiveness of tocilizumab (TCZ) therapy in COVID-19 patients. This research involved 68 patients diagnosed with severe and critical COVID-19 receiving Tocilizumab (TCZ) therapy at Universitas Indonesia Hospital. Blood type O was associated with a significantly improvement in CRP levels (P=0.014) and has better favorable outcomes compared to other blood type in terms of WHO Clinical Progression Scale (OR: 1.254, 95% CI: 0.457-3.443; P=0.797), length of stay (OR: 5,333, 95% CI: 0.495-3,734; P=0.614), and improvement in CRP levels (OR: 5,333, 95% CI: 1.385-20,541; P=0.014).
Keyword:
Blood Types, COVID-19, Interleukin-6 Inhibitors, SARS-CoV-2, Tocilizumab
Download full paper (PDF File size: 409.66 KB.)
|
